抄録
To improve compliance for pediatric patients with hypophosphatemic vitamin-D resistant rickets or Fanconi syndrome, we studied the preparation of a tablet for sodium phosphate using Fujicalin Sr and Avicel PH-F 20® as a direct-compression vehicle. Fujicalin S® and Avicel PH-F 20® consists of calcium phosphate dibasic and microcrystalline cellulose, respectively. The phosphorus content of the tablet increases by about 10% when using Fujicalin S® compared with Avicel PH-F 20®, which leads to a reduction in the dosage. The tablets prepared with Fujicalin S® showed a faster disintegration time and release rate than the tablets prepared with Avicel PHF 20®. However, the former showed an incomplete release profile in distilled water because of the insoluble property of calcium phosphate dibasic. On the other hand, the tablet prepared with Avicel PH-F 20® showed a sustained release of phosphoric acid and completely released the phosphorus in the tablet in distilled water. Phosphorus is reported to be absorbed from the gastrointestinal tract by the carrier-mediated transport. Thus, it was suggested that Avicel PH-F 20®was a better vehicle than Fujicalin 5® for regarding its clinical use.
